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 The public health burden of influenza is exacerbated by the continuous emergence 
of new strains and unanswered questions about viral spread within the host. Previously, 
groups have utilized reporter viruses encoding fluorescent proteins or luciferases to 
visualize real-time infection dynamics and elucidate complex interactions between 
viruses and host cells. In 2013, Tran et. al. developed a replication-competent influenza A 
reporter virus expressing nanoluciferase in the PA segment of a 1933 strain of H1N1, 
A/WSN/33, that closely mimicked wild-type virus behavior and replication dynamics. 
However, currently circulating strains of influenza are predominantly H3N2 viruses, 
urging development of a reporter influenza A virus that more closely represents the 
behavior of these modern strains. To address this need, we aimed to create two influenza 
A reporter viruses expressing nanoluciferase and the fluorescent protein mPlum in the PA 
segment of the A/Victoria/361/2011 strain of H3N2. Through various cloning techniques, 
the reporter genes were inserted at the end of the PA segment, and a reverse genetics 
approach was used to generate the two reporter viruses. Characterization of infectious 
titers and replication kinetics of the reporter viruses in cell culture (through TCID50 and 
plaque assays) demonstrated that the mPlum reporter virus, rA/Vic-mPlum, was slightly 
attenuated compared to the nanoluciferase reporter virus, rA/Vic-NLuc, and the wild-type 
virus, rA/Vic-WT. In addition, expression of mPlum fluorescent protein in the reporter 
virus could not be validated. However, rA/Vic-NLuc stably maintained luciferase activity 
and grew to higher titers and with similar kinetics as rA/Vic-WT. The results suggest 






assess the behavior of emerging H3N2 influenza viruses and further investigate influenza 
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CHAPTER 1: INTRODUCTION 
 
1.1 – INFLUENZA  
Overview 
Influenza is a respiratory disease that infects respiratory epithelial cells and causes 
mild to severe illness in humans. Symptoms of influenza infection include a rapid onset 
of fever, headache, cough, sore throat, runny or stuffy nose, myalgia, and fatigue.1 While 
influenza infection typically presents as an acute febrile respiratory tract infection, 
damage to the epithelial cell barrier can lead to systemic responses and increased 
susceptibility to secondary bacterial infections including pneumonia.2 Influenza disease 
in humans can be caused by Influenza A, B, or C viruses, however, infection with 
Influenza C virus causes very mild disease, while Influenza A and B viruses cause 
seasonal epidemics that result in moderate to severe morbidity globally.3 This thesis 
focuses on Influenza A virus (IAV).  
 
Epidemiology 
IAV is transmitted through respiratory droplets and aerosols that can travel up to 
six feet when an infected individual coughs, sneezes, or talks.4 In addition, IAV can be 
spread through contact with fomites, which can harbor infectious influenza virus particles 
for up to 8 hours.5 When a susceptible individual inhales respiratory droplets containing 
the virus, IAV attaches and infects epithelial cells of the upper respiratory tract.6 On 
average, the incubation period of IAV is 1.4 days before an individual develops 






develop. In addition, the average Ro value of seasonal Influenza A is 1.75, meaning that 
in a fully susceptible population a single infectious individual will transmit the virus to 
1.75 other individuals.7  
 
Public Health Concern 
While influenza is typically regarded as a mild illness, IAV infects 5-15% of the 
global population8 and causes hundreds of thousands of hospitalizations every year9. In 
the US alone, influenza causes 24,000 deaths annually, while the global count ranges 
between 250,000-500,000 deaths per year10. The populations that are at the highest risk of 
developing severe disease from influenza infection are young children and the elderly in 
addition to immunocompromised individuals and pregnant women.  
 
1.2 – INFLUNEZA GENOME & SOURCES OF DIVERSITY 
Virion structure 
Viral protein functions will be discussed in more detail later in this chapter, but a 
brief introduction is needed in order to discuss the clinical and public health significance 
of influenza. Influenza A virus is a negative single-stranded RNA virus and is part of the 
Orthomyxoviridae family (Figure 1). Its genome is comprised of 8 individual segments 
that replicate as autonomous units within an infected cell.11 On the surface of the 
influenza virus particle are the glycoproteins hemagglutinin (HA) and neuraminidase 
(NA). HA allows the virus to bind to receptors that contain sialic acid residues and infect 






cell.12 In addition to these surface proteins, the matrix 2 protein (M2) sits within the viral 
lipid bilayer and plays a critical role in viral entry, uncoating, autophagy inhibition, and 
the production of infectious influenza virus particles.13 In comparison, the inner surface 
envelope matrix 1 protein (M1) functions during virion assembly and budding.  
The core of the influenza virus contains the viral RNA segments that encode these 
proteins in addition to several others. The PB1, PB2, PA segments that form the influenza 
RNA-dependent RNA polymerase complex and the influenza nucleoprotein (NP) that 
protect the viral genome during replication are also contained in the core of the virion.14 
The nuclear export protein (NEP or NS2) plays an important role in shepherding the viral 
gene segments from the nucleus to sites of virus particle budding. Lastly, the non-
structural protein, NS1, encoded in the NS segment, has a variety of roles including host 
antiviral gene expression inhibition, but is not packaged into virus particles at an 
appreciable amount.15 
 
Antigenic Drift – HA  
Influenza is continuously evolving and pushing the boundaries of the global 
public health response. One of the reasons for this rapid evolution is influenza has a 
genome made of RNA, and RNA polymerases lack the proofreading mechanism present 
in DNA polymerases.16 Therefore, any errors or mutations made during the replication of 
the influenza genome are maintained. In cases where these mutations are beneficial to 
viral fitness, the virus survives in the population and outcompetes weaker influenza 






involve changes to the surface glycoprotein HA. Changes to the HA sequence can allow 
the virus to avoid detection by host antibodies and "drift" away from current vaccine 
formulations.17 This process of antigenic drift dictates the need to reevaluate the strains 
included in the influenza vaccine every year to assure protection against current HA 
surface antigens.  
 
Antigenic Drift – NA  
While NA antigenic drift occurs less frequently than HA drift, NA plays a key 
role in mediating protection from influenza. The enzymatic activity of NA is essential for 
the release of virus particles from an infected cell and allows IAV to be transmitted in 
small droplets.18 Previous studies demonstrated an association between high anti-NA 
antibody titers and less severe symptoms and lower levels of viral shedding.19 More 
recently, data show that anti-NA antibodies can protect mice from lethal challenge with 
IAV, and anti-NA antibodies bind with remarkably broad specificity unlike their HA 
counterparts.20 Despite these data, current influenza vaccine production does not 
standardize quantification of the NA component in vaccines, nor do current vaccines 
induce NA-reactive B cells.21 Further attention should be paid to the NA component of 










1.3 – PANDEMIC INFLUENZA 
Animal Reservoirs 
Migratory waterfowl are the primary reservoir of influenza A viruses including all 
16 subtypes of hemagglutinin and 9 subtypes of neuraminidase.22 In these species, 
influenza infection usually presents as a minor gastrointestinal disease rather than an 
infection of the respiratory tract, and influenza viruses infect the epithelial cells of the 
intestines that express primarily α2,3- sialic acid linkages. Comparatively, human 
respiratory epithelial cells contain sialic acids linked to the penultimate galactose through 
mainly α2,6- linkages.23 Domesticated poultry can also serve as animal reservoirs for 
influenza viruses and HA subtypes H5, H7, and H9 circulate naturally in these 
populations. In addition to avian species, swine carry influenza virus strains that circulate 
exclusively in that species. Influenza A viruses that circulate in swine have already 
overcome a number of species barriers that prevent avian influenza viruses from 
efficiently infecting mammals. Swine may also serve as intermediate hosts, or “mixing 
vessels” for influenza viruses from different species (avian, human, etc.). The epithelial 
cells in the respiratory tract of pigs contain high amounts of both Siaα2,3Gal and 
Siaα2,6Gal sialic acid linkages and can therefore be infected by influenza viruses arising 
from both avian and human sources.  
 
Public Health Impact 
In six months, the Great Influenza pandemic of 1918 infected one-third of the 






than the casualties of both World War I and II combined, the 1918 influenza defined 
many of the infectious disease control measures still practiced today. The genome of the 
virus that was responsible for the pandemic in 1918 contained all 8 segments from avian 
species and was completely novel to humans in all aspects. In 1957, the Asian Flu 
emerged as a reassortant of the 1918 H1N1 virus and an H2N2 virus. Another avian 
human influenza virus reassortment led to the H3N2 influenza pandemic of 1968. Most 
recently, in 2009, the “Swine Flu” H1N1 pandemic emerged as a triple reassortant virus 
containing original segments from avian, human, and swine influenza viruses and appears 
to have been a result of a direct swine to human transmission event.25  
 
Antigenic Shift 
The segmented genome of IAV allows it to reassort with other IAV strains to 
generate viruses with new gene segment combinations very easily. When a single cell is 
infected with two or more influenza virus strains, the eight segments of the genome can 
shuffle together, generating a new virus particle that contains a mix of segments from 
either of the two original viruses.11 For example, if a single cell is infected with two 
different influenza viruses, there are 254 potential variants can emerge as a result of the 
co-infection event. While this process of reassortment allows influenza to regulate viral 
fitness to maintain circulation and survival within a population, a possible combination of 







Humans have been exposed to influenza HA types 1, 2, and 3 naturally over the 
course of evolution, however, there is no pre-existing immunity against the other HA 
subtypes in the broader human population. As a result, when viruses of the other HA 
subtypes from animals cross the species barrier into humans, a pandemic can emerge if 
there is sustained human-to-human transmission of the new virus. This phenomenon is 
referred to as antigenic shift and is the reason behind the pandemics of 1918, 1957, 1968, 
and 2009. For a virus to cross the species barrier from either avian or swine species into 
humans, the influenza virus must be able to 1) attach to the surface of human cells 2) 
replicate its RNA inside human cells 3) inhibit aspects of the immune response to 
infection and 4) overcome the temperature barrier to be able to replicate at lower 
temperatures.26 
 
1.4 – ISSUES WITH INFLUENZA CONTROL 
Challenges 
Influenza continues to challenge modern public health systems due to its unique 
genetic structure and widespread global presence. First, the virus causes yearly epidemics 
that arise from unpredictable antigenic drift. As an RNA virus, influenza lacks the 
proofreading mechanisms involved in viral transcription that are present in both DNA 
viruses and human DNA. When minor errors in transcription occur, there is no repair 
mechanism to fix the mutations and either the conferred mutations hurt the virus and it 






itself well in the population. Moreover, these rapid changes in viral RNA can lead to 
antiviral drug resistance.27  
Another challenge with influenza control is the inefficient and timely process of 
vaccine development. Influenza vaccines are grown in embryonated hen’s eggs where 
each infected egg generates 1-3 vaccine doses.28 To make the vaccine, the HA and NA 
surface glycoproteins from circulating or emerging flu strains are mixed with internal 
genes of a well-characterized vaccine virus that is adapted for growth in eggs. However, 
if the selected HA and NA genes result in a virus that cannot grow well in eggs, the virus 
can no longer be used as the vaccine due to manufacturing limitations.29 Vaccine strains 
are typically chosen in March of every year based off circulating viruses from the 
previous year. Yet, in March, the flu season is still not fully over, and selected vaccine 
viruses may miss emerging strains that arise at the end of the flu season. For example, in 
2003, an A/Fujian H3N2 virus emerged in the month of March, but the number of 
isolates was small compared to the A/Panama/2007/99 vaccine strain isolates. Moreover, 
attempts to try to grow the A/Fujian strain in eggs failed.30 Because there are no approved 
alternate technologies for influenza vaccine production and because the number of 
isolates of A/Fujian were limited, the virus was not included in the final vaccine selection 
for the 2003-2004 season. Consequently, manufacturers maintained the A/Panama strain 
in the vaccine and the cases of H3N2 that emerged in the 2003-2004 season were all 
A/Fujian strains, resulting in very low vaccine efficacy.31 Cases like the vaccine 
mismatch in 2003 serve as a reminder of the inefficient and costly production of 






vaccine that can target more conserved regions of the virus to induce protection for 
multiple years at a time.  
 
1.5 – INFLUENZA REPLICATION 
Overview 
The replication of influenza viruses is a complex process that is carried out by 
genes encoded on multiple segments of the influenza genome and takes place within the 
nucleus of an infected cell. Inside the nucleus, the virus can avoid detection by antiviral 
responses common in the host cytoplasm. In addition, the nucleus of the cell contains the 
highest concentration of host messenger RNA as well as splicing machinery that can be 
hijacked by the influenza virus. Together, the polymerase acidic protein (PA) and 
polymerase basic proteins 1 and 2 (PB1, PB2) form a heterotrimer that functions as the 
RNA-dependent RNA polymerase (RdRp), Figure 2. NP is also involved in viral 
replication, and encapsidates the viral genome to form the ribonucleoprotein (RNP) that 
protects RNA during transcription and packaging.32 Upon viral entry into the host cell, a 
low pH pulse mediated by the M2 protein frees the RNPs from the M1 protein. This 
process unmasks nuclear localization signals (NLSs) contained in the NP core of the 
RNPs and facilitates the active transport into the host nucleus.33,34 Normally, proteins 
only 40-50 kDa in size can passively enter through nuclear pores, while these RNPs can 








Replication of Genomic vRNAs and Transcription of mRNAs 
The influenza RdRp is used to both replicate viral genomic RNA and to generate 
mRNA for the translation of viral proteins. Once inside the nucleus, the viral genomic 
RNA (vRNA) is both replicated through complimentary RNA (cRNA) intermediates and 
transcribed into mRNA for the production of viral proteins.35,36 Recent studies suggest 
the interaction between PA and the minichromosome maintenance (MCM) complex 
allows stabilization of the polymerase complex that supports the full elongation of 
vRNAs during the synthesis of cRNAs.37 However, the exact role that the PA segment 
plays in this replication of vRNA is not well characterized.38  
To generate mRNA, the PB2 segment of the RdRp facilitates the “cap-snatching” 
phenomenon by binding to the 5’ methylated caps of host cell mRNA and stealing these 
sequences as primers for generation of its own viral RNA. The 5’ caps are then cleaved 
by an endonuclease encoded in the PA subunit of the RdRp and are used by PB1 as 
primers for the transcription of viral mRNAs.39 Eventually the 5’ end of the viral 
genomic RNA is still bound by PB1 and the polymerase lacks the strength to pull this 5’ 
end away, leaving approximately 20 nucleotides stuck in the RdRp complex. This 
sequence is preceded by a stretch of uridines, and as the viral polymerase engages in a 
tug-of-war with the RNA, the polymerase stutters across this uridine-rich region, 
generating a string of adenosine nucleotides on the end of the mRNA that serve as the 
poly-A tail required for replication.40 These newly generated positive-sense mRNAs can 
then be exported to the cytoplasm for the translation of viral proteins,41 which are 






mediates cleavage of HA from sialic-acids on the host cell and allows detachment and 




Viruses that are engineered to express virus-inducible reporter genes with 
fluorescent or enzymatic activity are termed reporter viruses. The concept of using 
fluorescent proteins to study molecular interactions between a host and pathogen is 
incredibly useful and has a large range of potential applications. For example, in 2011 
researchers engineered dengue reporter viruses of serotypes 1-4 that expressed green 
fluorescent protein (GFP). These reporter viruses were used to quickly determine 
neutralizing antibody titers from human serum samples, and suggest an alternate 
approach of quantification besides traditionally used plaque reduction neutralization tests 
(PRNT).42 Other groups have also used dengue reporter viruses to visualize viral 
replication concentrated in the lymphoid and gut-associated tissues of mice, and were 
successful in demonstrating how this localization changes over time.43  Besides dengue 
reporter viruses, in 2014, the Freeman et al. group used a murine hepatitis reporter virus 
to elucidate the targeting and activity of replicase proteins during infection.44 Measles is 
also another virus that has been engineered frequently as reporter viruses to study 
pathogenesis and cellular interactions; in 2016 Singh et al. created a GFP-labeled measles 






a few examples of how reporter viruses are useful for both in vitro and in vivo exploration 
of virus-host interactions.  
 
Influenza A Reporter Viruses, Challenges, and Applications 
Similar to the applications discussed above, influenza A reporter viruses have 
been used to explore neutralizing antibody screening techniques, antiviral compound 
efficiency, cell tropism, critical host factors, and vaccine development possibilities.46 
However, IAV presents unique challenges to scientists attempting to construct influenza 
A reporter viruses. First, influenza poorly tolerates gene insertions. Second, viral 
replication of reporter viruses is often attenuated in vitro, in vivo, or both. Finally, 
inserting fluorescent genes at the ends of influenza gene coding regions can disrupt 
packaging signals that are required for assembly of the virus particle. These challenges 
are demonstrated more in depth with examples of previous work generating influenza A 
reporter viruses.  
The first attempts to generate influenza reporter viruses were made in 2004 by 
groups at the Institute of Applied Microbiology in Vienna, Austria and the Institute of 
Medical Science at the University of Tokyo. Both attempts involved replacing regions of 
the NA or NS1 segments with GFP, and the groups demonstrated reporter virus 
attenuation47 and decreased pathogenesis in mice.48 Other research groups tested Gaussia 
luciferase insertion, rather than GFP, into the PB2 and NA segments of A/PR/8/34. While 
these reporter viruses demonstrated strong fluorescence in vivo, there was significant 






reporter genes, including luciferases, into the NS segment of a 1934 H1N1 strain from 
Puerto Rico (A/PR/8/34). However, their attempts either resulted in background levels 
that were too high for detection, reporter virus attenuation, or loss of reporter expression 
after passaging in cells.50 In order to increase the stability and pathogenicity of the 
Manicassamy et al. generated influenza reporter viruses, Fukuyama et al. serially 
passaged the reporter virus in mice.51 While this did slightly improve pathogenicity and 
stability of the reporter virus, their experiments used the NS reporter gene construct from 
the A/PR/8/34 H1N1 strain in the context of an H5N1 backbone. Therefore, any 
conclusion drawn from the behavior of this reporter virus may not accurately depict 
behavior of the wild-type virus. Moreover, the group identified two mouse-adapted 
mutations in the HA and PB2 segments of the reporter virus following passage.  
In 2013, a group led by Andrew Mehle at the University of Wisconsin Madison 
constructed a relatively stable influenza reporter virus using the PA segment from a 1933 
strain of H1N1 (WSN) with nanoluciferase as the reporter gene.52 The construct design 
that demonstrated the lowest levels of reporter virus attenuation is shown in Figure 3. In 
this design, the PA packaging sequence was moved to the end of the segment following 
the nanoluciferase gene, in order to avoid disrupting the critical role this sequence has in 
packaging the segment into a complete virion. The group also included silent mutations 
where the packaging sequence used to be to ensure any direct repeats were removed and 
transcription would proceed with the nanoluciferase gene. Lastly, the construct by Tran et 
al. included a 2A self-cleaving peptide from a picornavirus to allow cleavage of the 







Reporter viruses are invaluable for visualizing real-time infection dynamics and 
may help elucidate complex interactions between viruses and host cells. In this project 
(Figure 4), a fluorescent protein, mPlum (far-red), and a nanoluciferase reporter, NLuc, 
will be inserted into the PA segment of the A/Victoria/361/11 (A/Vic) H3N2 influenza 
virus isolated in 2011. Packaging signals of the PA segment will be moved to the end of 
the construct to allow complete expression of the reporter genes. Silent mutations will 
also be inserted into the PA gene to optimize for expression in human cells. The PA-
reporter gene construct will then be utilized in a reverse genetics approach to create 
reporter viruses. Following successful generation of the PA reporter virus, comparative 
infection studies will help determine any effects of the inserted reporter genes on virus 
replication compared to the wild-type virus. Later, the reporter construct can be used in 







CHAPTER 2: REPORTER CONSTRUCT CLONING & 
EXPRESSION 
 
2.1 – BACKGROUND 
Selection of Reporter Genes 
The reporter viruses that were generated as part of this project incorporated the 
genes encoding either the fluorescent protein mPlum or the small enzyme nanoluciferase 
(NLuc). These reporter genes were selected for their range of potential application in 
vitro and in vivo. 
mPlum is a 681-base pair far-red monomeric protein that emits light when 
exposed to wavelengths around 649 nanometers (nm). As the deepest colored fluorescent 
protein in the far-red spectrum, which ranges from 630-700nm, mPlum is useful for 
imaging specimens that may otherwise have naturally high levels of green 
autofluorescence.53 In addition to this preferred low signal to noise ratio, expression of 
mPlum can be detected directly when imaging within the Cy5 channel, and therefore does 
not require addition of a substrate to induce fluorescence. These characteristics make 
mPlum particularly useful in live animal imaging when a substrate cannot be given 
systemically and there is a need to minimize autofluorescence. Moreover, mPlum has 
excellent photostability and can be used in multicolor imaging applications with 
fluorescent proteins emitting at lower wavelengths.54 However, despite these benefits, the 
far-red fluorescent proteins are known for lower than desired brightness, which may 







The other reporter protein selected for generating an influenza A reporter virus is 
nanoluciferase (NLuc), which was used previously by Tran et al.52 NLuc is a genetically 
modified luciferase that is expressed naturally in a deep-sea shrimp and is much smaller 
and brighter than traditional luciferases. NLuc is only 513-base pairs and 19 kDa 
compared to Renilla, and Firefly luciferases at 36 and 61 kDa respectively. NLuc is also 
approximately 100-fold brighter than either of these more commonly used luciferases.56 
As a result of its small size, NLuc is able to penetrate thicker tissues in vivo. Similar to 
mPlum, NLuc is also highly stable both in vitro and in vivo, and it retains its enzymatic 
activity even after a 15-hour incubation at 37°C. This is particularly useful for imaging 
influenza infections since most cell lines are incubated at this temperature.  
 
Use of Mammalian Expression Vector 
pCAGGS is a eukaryotic expression plasmid that was developed in the early 
1990’s and includes a chicken β-actin promoter. Foreign genes inserted into the pCAGGS 
plasmid are efficiently expressed, and the system presents a way to quickly validate 
cloning products or generated segments.57 Following synthesis of the PA-reporter gene 
segments, pCAGGS will be used for a series of expression experiments including western 
blot and fluorescent microscopy to confirm PA and reporter gene expression in the newly 
generated constructs. This process will ensure that the PA-reporter products used for 
reverse genetics and subsequent virus rescue are correct and be useful for optimizing 






2.2 – METHODS: CLONING 
Generation of the PA-Reporter Constructs 
mPlum 
The mPlum sequence was isolated via restriction digest from the pCAGGS-
mPlum plasmid. The restriction digest set up included 1µl of Nhe1-HF and Sac1-HF 
(New England Biolabs), 2.2µl of pCAGGS-mPlum DNA (0.57µg/µl), 5µl CutSmart 
Buffer, and 40.8µl nuclease-free water. An undigested control was set up with 2.2µl of 
pCAGGS-mPlum DNA (0.57µg/µl), 5µl CutSmart Buffer, and 42.8µl nuclease-free 
water. The reactions were incubated at 37°C for 18 hours and the products were loaded 
into a 1% agarose gel and run at 200V for 1 hour (Figure 5). The 683bp mPlum DNA 
band was extracted from the gel and purified using QIAquick Gel Extraction Kit 
(Qiagen). The mPlum DNA concentration (7.9 ng/µl) was measured with the NanoDrop 
spectrophotometer ND-1000 (Thermo Fisher Scientific).  
 
Overlap Extension PCR 
Oligos containing the terminal 50 nucleotides of PA including the 3’UTR 
(PAt50), which encode necessary packaging signals, were ordered from IDT (Appendix). 
The oligos were annealed together and diluted with duplex buffer to a final concentration 
of 50µM. Primers were designed and ordered (IDT) to add a sequence to the 5’ end of 
PAt50 that overlaps with the 3’ end of mPlum. Similarly, primers adding a 15bp 






Polymerase (New England Biolabs) was used to add the overhanging nucleotides to both 
segments with the following cycling conditions: 
98°C 30 seconds 
98°C 10 seconds 
x35 cycles 
mPlum = 68°C 
PAt50 = 64°C 
30 seconds 
72°C 1 minute 
72°C 5 minutes 
10°C Hold 
 
An overlap extension PCR using Phusion® was set up to stitch together the 
mPlum-OH and OH-PAt50 sequences to generate mPlum-PAt50. The overlap extension 
PCR results were run on a 1% gel at 200V for 1 hour alongside the negative control, 
mPlum-OH. The size difference in the top bands indicated that the PCR was successful in 
generating mPlum-PAt50 (Figure 6).  
 The 2235 base pair PA segment containing the 5’ UTR with silent mutations, the 
GSG linker and the 2A protease was ordered as a gBlocks Gene Fragment from 
(Integrated DNA Technologies). This segment, now referred to as PA_GSG_2A, was 
resuspended in TE buffer to a final concentration of 10ng/µl.  
 
Nanoluciferase 
A gBlocks® Gene Fragment of nanoluciferase containing the terminal 50 
nucleotides of the PA segment was ordered from IDT and resuspended with TE buffer to 










The Gibson Assembly technique was used to clone the PA_GSG_2A and mPlum-
PAt50 segments into the pCAGGS mammalian expression plasmid. First, Phusion® PCR 
was used to add overlapping nucleotides to both the 5’ and 3’ ends of PA_GSG_2A and 
mPlum-PAt50. The pCAGGS-mPlum plasmid was linearized with restriction enzymes 
Nhe1-HF and Sac1-HF at 37°C for 18 hours and inactivated at 65°C for 20 minutes. The 
linearized pCAGGS plasmid with mPlum removed was purified from a 1% agarose gel 
using QIAQuick Extraction Kit (Figure 7) and PCR was used to add nucleotides 
overlapping with the PAmut-2A and mPlum-PAt50 to the 3’ and 5’ ends, respectively. 
The Gibson Assembly reaction was set up with 50ng each of pCAGGS, PAmut-
2A, and mPlum-PAt50 with the overlapping regions, Gibson Assembly MasterMix (2x), 
and nuclease-free water. The reaction was incubated at 50°C for 60 minutes and 
immediately chilled at -20°C for subsequent transformation. Gibson Assembly products 
were transformed in NEB 5-α Competent E. coli cells provided with the kit. 2µl of the 
assembly reactions were added to tubes containing 50µl of the 5-α cells. The samples 
were mixed gently by flicking and set on ice for 30 minutes. Tubes were heat shocked at 
42°C for 30 seconds to allow the DNA to enter the bacterial cells, and then placed on ice 
for 5 minutes. 950µl of room temperature SOC media was added to each tube and 
transferred to a 37°C shaker at 250rpm for 1 hour. LB agar plates containing 100 mg/ml 
carbenicillin were warmed to 37°C. 100µl of the transformed cells were spread onto the 






Bacterial colonies were then screened for the Gibson Assembly products of 
interest. Colonies were grown in overnight cultures of 3ml of LB with 100mg/ml 
carbenicillin at 37°C. The following day, plasmid DNA was purified using QIAprep Spin 
Miniprep Kit (Qiagen) and the concentration was measured using the ND-1000 
spectrophotometer (Thermo Fisher Scientific). All samples were run on a 1% agarose gel 
and band size was evaluated. Samples with the appropriate molecular weight were 
selected for further sequencing analysis using multiple sets of primers specific for 
pCAGGS and internal sequences of PA and mPlum (Table 2). Sequencing was 
performed by the Genetic Resources Core Facility at the Johns Hopkins University 
Institute of Genetic Medicine using the Applied Biosystems 3730xl DNA Analyzer. The 
ZymoPURE™ Plasmid Maxiprep Kit (Zymo Research) was used to amplify the 
pCAGGS-PA-mPlum Gibson Assembly product verified by sequencing. This maxiprep 
sample was used in subsequent expression experiments including immunofluorescence 
following an additional sequencing confirmation.  
 
Nanoluciferase 
The NLuc-PAt50 segment was PCR amplified with primers to add an additional 
15 nucleotides on both the 3’ and 5’ ends to overlap with the PAmut-2A and pCAGGS 
segments, respectively. The PAmut-2A and linearized pCAGGS segments were also PCR 
amplified to add overlapping regions with the NLuc-PAt50 segment. 
The Gibson Assembly reaction was set up using the PCR products with 






2A, and 150ng NLuc-PAt50 (all with overlapping regions) were incubated with 10µl of 
10x Gibson Assembly MasterMix and 0.5µl of nuclease-free water for 60 minutes at 
50°C. Following the reaction, assembly products were immediately chilled at -20°C and 
transformed in NEB 5-alpha Competent E. coli cells as described above for the mPlum 
transformations. Plasmid DNA was isolated from overnight cultures of selected bacterial 
colonies and run on a 1% gel for molecular weight verification.  
Sanger sequencing was performed on selected samples as described above and the 
ZymoPURE™ Plasmid Maxiprep was used to amplify the sample with correct 
sequencing. This sample was verified by sequencing again and used for further 
expression experiments including Western Blot and the Nano-Glo® Luciferase Assay. 
 
Site-directed mutagenesis of pCAGGS-PA-mPlum 
Sanger sequencing of the pCAGGS-PA-mPlum plasmid revealed an additional T 
nucleotide at base 3,020 within the PA segment. This mutation causes a frameshift 
downstream that disturbs translation of the correct proteins. The QuikChange Lightning 
Site-Directed Mutagenesis Kit (Agilent Technologies) was used to remove this additional 
nucleotide. Two individual mutagenic oligonucleotide primers were designed to include 
the desired deletion in the middle of the primer, with 15 bases of correct sequence on 
both sides. The primers used are listed in Table 1.  
A site-directed mutagenesis mutant strand synthesis reaction was set up 






Lightning Enzyme, QuikSolution Reagent, 10x QuikChange Lightning Buffer, and 
nuclease-free water.   
The cycling conditions used were: 
 
95°C 2 minutes 
95°C 20 seconds 
x18 cycles 66°C 30 seconds 
68°C 4 minutes 
68°C 5 minutes 
4°C Hold 
 
Following thermal cycling, Dpn1 restriction enzyme was added directly to each 
amplification reaction to digest the parent strand of DNA, leaving only the mutant strand 
remaining. The reaction mixes were mixed thoroughly and incubated at 37°C for 5 
minutes. After Dpn1 digestion, the samples were transformed in XL10-Gold 
ultracompetent cells (Agilent Technologies). 45µl of cells were added to a pre-chilled 14-
ml BD Falcon round-bottom tube and 2µl of beta-mercaptoethanol was added. Cells were 
incubated with the β-ME for 2 minutes on ice. 2µl of the Dpn1 digested product was 
added to the tube of cells and incubated on ice for 30 minutes following gentle mixing by 
swirling. The cells were heat shocked at 42°C for 30 seconds and immediately placed 
back on ice for 5 minutes. 950µl of pre-warmed (37°C) LB broth was added to the tube 
and incubated at 37°C for 1 hour with shaking at 250rpm. 200µl of the transformed cells 
were added to pre-warmed (37°C) LB-carbenicillin agar plates and incubated overnight at 









Colony Screening and Sequence Analysis 
The QIAprep Spin Miniprep Kit (Qiagen) was used to purify plasmid DNA from 
the site-directed mutagenesis pCAGGS-PA-mPlum samples. The sample DNA were 
submitted for Sanger sequencing. Sequencing results revealed the G nucleotide at 
position 3,019 immediately preceding the additional T nucleotide was deleted during the 
site-directed mutagenesis process, but the additional T mutation remained. However, the 
deletion of the guanine corrected the frameshift of downstream nucleotides. As a result, 
there is a W422L mutation in the PA segment (Figure 8). The PA segments from 15 
other H3N2 sequences were analyzed for this mutation, however the tryptophan at 
position 422 is conserved throughout all 15 viruses (Figure 9). For the sake of timeliness, 








2.3 – METHODS: EXPRESSION VALIDATION 
Cell Lines 
Madin Darby canine kidney (MDCK) and HEK 293T (293T) cells were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) with 10% fetal bovine 
serum (FBS, Gibco Life Technologies), 100U penicillin/ml with 100µg streptomycin/ml 
(Quality Biological), and 2mM L-Glutamine (Gibco Life Technologies) at 37°C with air 
supplemented with 5% CO2.  
 
Nano-Glo® Luciferase Assay  
Activity of the nanoluciferase encoded in the pCAGGS-PA-NLuc plasmid was 
measured by the Nano-Glo® Luciferase Assay System (Promega). Because 
nanoluciferase is an enzyme, it needs a substrate in order to function and emit light. The 
Nano-Glo® Luciferase Assay System allows detection of luciferase activity in 
mammalian cells using either a lytic or non-lytic method. In this experiment, the lytic 
method was used to measure nanoluciferase activity from both intracellular and secreted 
forms of nanoluciferase. The plasmid pNL1.1-NLuc used as a positive control was 
generously provided by Andrew Mehle at the University of Wisconsin.  
MDCK cells were grown to confluence and transfected in at least triplicate in a 
96-well plate using Lipofectamine3000 (Thermo Scientific). Cells were transfected with 
0.2ug DNA per well of either the pCAGGS-PA-NLuc plasmid, pNL1.1-NLuc, or 
Lipofectamine alone as a negative control. Plates were incubated at 37°C, 5% CO2 for the 






removed from the incubator and allowed to equilibrate to room temperature. The Nano-
Glo® Luciferase Assay Substrate was added to the Nano-Glo® Luciferase Assay Buffer at 
a 1:50 ratio to generate the Nano-Glo® Luciferase Assay Reagent. The reagent was 
equilibrated to room temperature. 100µl of Nano-Glo® Luciferase Assay Reagent was 
added per well and incubated at room temperature for 5 minutes. Luminescence was 
measured using the Molecular Devices Filter Max F5 Multi-Mode Microplate Reader 
with SoftMax Pro 6.4 software. 
 
Western Blot for PA in pCAGGS-PA-NLuc  
Western blots were performed to evaluate if PA expression was retained in the 
generated pCAGGS-PA-NLuc construct. Addition of reporter genes can inhibit 
expression of PA due to potential protein misfolding. However, detection of PA in this 
experiment is not necessarily indicative of polymerase activity, since the other 
polymerase subunits PB1 and PB2 were not co-transfected with the pCAGGs-PA-NLuc 
plasmid.  
293T cells were transfected in suspension at 1x106 cells/ml in a poly-L-lysine 
(Sigma-Aldrich) coated 6-well plate. Cells were transfected with 4ug/well of the 
pCAGGS-PA-NLuc plasmid with Lipofectamine3000. Plates were incubated at 37°C, 5% 
CO2 for 48 hours. Media was replaced after 24 hours. 293T cells were also infected with 
A/Victoria/361/11 at an MOI of 0.5. Following transfection and infection, cells were 
washed with PBS supplemented with 100g/L Ca2+ and Mg2+ (PBS+). Cells were lysed 






Single-Use Cocktail, EDTA-Free (ThermoScientific). Cells were scraped with a pipet tip 
and transferred to an Eppendorf tube. A 20-gauge needle was used to homogenize the 
lysates. Lysates were then centrifuged at 12,000 rpm for 15 minutes at 4°C and 
supernatants were stored at -20°C for future use.  
Isolated cell lysates were thawed and mixed with 4x Laemmli Sample Buffer 
(BioRad) and 50mM DDT (Pierce). No protein concentration assay was performed 
because β-actin levels were used to normalize total protein content. Samples were boiled 
for 5 minutes at 100°C and placed on ice immediately. Samples were then separated on a 
4-15% Mini-PROTEAN TGX Precase Gels (Bio-Rad) at 150 volts for 40 minutes. 
BioRad Precision Plus Blue Only protein ladder was used as a standard.  
Gels were transferred to polyvinylidene fluoride Immunobilon-FL membranes 
(PVDF; Millipore) for 1 hour at 100 volts. Ice packs were added to keep the transfer 
chamber cold to avoid overheating the membranes. Membranes were washed with PBS 
containing 0.2% Tween-20 (Sigma-Aldrich) and transferred to a blocking buffer solution 
of PBS, 0.2% Tween-20, and 5% Nonfat Dry Milk (Bio-Rad) at 4°C overnight. The 
following day, primary antibodies were added to the membrane and incubated on a plate 
rocker overnight at 4°C. The primary antibodies used were Monoclonal Anti-Influenza A 
Virus Polymerase Acidic Subunit (PA), Clone F1-2C3 (BEI Resources, NR-31685) 








The membranes were washed at 4°C three times for 5 minutes each and incubated 
with secondary antibodies for 1 hour at room temperature. AlexaFluor 657-conjugated 
secondary antibodies used included a donkey anti-mouse immunoglobulin G and a 
donkey anti-rabbit immunoglobulin G at 1:500 and 1:1,000 dilutions, respectively. The 
membranes were washed again at 4°C three time for 5 minutes each and then imaged. 
Visualization was performed using the FluorChemQ phosphorimager (ProteinSimple). 
                                                                                                                                                                                                                                                                                                                                                      
Fluorescence Microscopy of mPlum in pCAGGS-PA-mPlum 
Vero cells were transfected with the pCAGGS-PA-mPlum generated construct 
and the pCAGGS-mPlum plasmid as a positive control. Cells were also mock transfected 
as a negative control. 4µg of plasmid DNA was used to transfect the cells with 
Lipofectamine3000 in a 6-well plate with 1x106 cells/ml in suspension. Two coverslips 
per well were placed prior to addition of the cells for transfection. Plates were incubated 
at 37°C, 5% CO2 for 48 hours with media replaced after 24 hours. After 48 hours, media 
was removed and cells were washed gently three times with PBS+. 1ml of 4% 
paraformaldehyde (Affymetrix) was added per well and incubated at room temperature 
for 15 minutes. The cells were washed again three times with 1ml PBS+ per well. 1ml 
PBS with 0.2% Triton X-100 (Sigma) was added per well and incubated at room 
temperature for 15 minutes to permeabilize the cells. Coverslips were carefully mounted 







2.3 – RESULTS 
Nano-Glo® Luciferase Assay 
Nanoluciferase activity was measured in relative light units normalized to mock. 
At 12, 24, and 48 hpt, the activity levels of nanoluciferase in the pCAGGS-PA-NLuc 
construct were at least ten-fold higher than those of the positive control pNL1.1-NLuc 
(Figure 10). pCAGGS contains a chicken beta-actin promoter with enhancer activity, and 
it is likely that the pNL1.1-NLuc plasmid kindly provided by Dr. Mehle has a less active 
promoter. This Nano-Glo® Luciferase Assay will later be used to test the luciferase 
activity of a rescued influenza reporter virus encoding nanoluciferase.   
 
Western Blot 
PA was detected at the expected 83kDa size58 in the pCAGGS-PA-NLuc 
transfected and A/Victoria/361/11 infected cell lysates using anti-PA antibodies (Figure 
11). β-actin protein (42kDa) served as the positive control and was detected in all of the 
samples, including the mock transfected cells. Detection of PA in the pCAGGS-PA-
NLuc samples indicate that the addition of the NLuc genes to the PA segment does not 
disrupt translation of the PA protein. Western blots were not performed for pCAGGS-
PA-mPlum transfected cells in the interest of time. Because of this, it is possible that 
there is limited PA expression. For both NLuc and mPlum constructs, the presence of PA 
alone does not suggest successful polymerase activity. To analyze this, the other 








Fluorescence Microscopy of mPlum in pCAGGS-PA-mPlum 
Fluorescence microscopy was used to determine the expression of the mPlum 
protein in Vero cells transfected with pCAGGS-PA-mPlum (Figure 12). The pCAGGS-
mPlum positive control transfected coverslips reveal clear mPlum expression when 
imaged with the Cy5 channel on the Zeiss M2 microscope. Protein expression appears to 
be diffuse within the cell and not restricted to the nucleus alone. In the mock transfected 
coverslips, nuclei were stained blue with DAPI and clearly imaged, but no mPlum was 
detected with the Cy5 channel. The pCAGGS-PA-mPlum transfected Veros imaged with 
Cy5 did show some detectable levels of mPlum production. mPlum expression was also 
seen in cells transfected with the pCAGGS-PA-mPlum construct; although at lower 
levels than the pCAGGS-mPlum transfected cells. While mPlum levels are visually lower 
than those produced in pCAGGS-mPlum transfected cells, they are higher than the 
baseline mock values. Therefore, it appears that the translation of the mPlum protein still 
occurs when adding the protein encoding genes within the PA segment. 
 
Conclusions 
The data presented demonstrate that both mPlum and NLuc activity are present in 
plasmid DNA expressed constructs containing the reporter genes fused to the PA protein 
with a self-cleaving protease domain between the two proteins. This indicates that the 
basic strategy of expressing cleavable reporter genes fused to the PA protein results in 






of the PA-NLuc fusion protein. These positive results allowed us to proceed to the rescue 






CHAPTER 3: REPORTER VIRUS CHARACTERIZATION 
3.1 – INTRODUCTION 
Background 
Previously generated influenza reporter viruses have suffered from attenuation in 
vivo, in vitro, or both, and do not closely represent modern, currently circulating strains 
of influenza. The objective of this project was to generate a reporter influenza A virus 
within the A/Victoria/361/2011 background that encodes for mPlum or nanoluciferase 
within the PA segment. Once the PA-reporter constructs were successfully validated in 
the pCAGGS mammalian expression vector (Chapter 2), they were moved into the 
pHH21 plasmid and used in a 12-plasmid based recombinant virus rescue system.59,60 
pHH21-PA-reporter plasmids take advantage of the unique restriction digest products 
following BsaI and BsmBI digestion, which create inserts with the same nucleotide 
overhangs on both the 5’ and 3’ ends, allowing a single step ligation process to transfer 
the PA-reporter genes into the pHH21 plasmid.  
 
Reverse Genetics Approach 
All eight segments are required to make a functional virus, but because these 
segments are negative sense RNA strands, they are noninfectious and cannot be used as 
templates for translation. Therefore, plasmids expressing viral replication machinery 
proteins are necessary to include in order to achieve virus protein expression and 
complete the virus replication cycle. When plasmids encoding the eight influenza 






assemble into functional viral RNPs. Inclusion of the polymerase-containing replication 
machinery helper plasmids allows these viral RNAs to be replicated to produce more 
infectious viral particles.36 This reverse genetics system is effective because the pHH21 
plasmids contain pol I promoters, and cellular RNA polymerase I is abundantly expressed 
in mammalian cells. Moreover, previous literature revealed that 293T cells are easily 
transfected61 and are best suited for this reverse genetics approach.   
 
Virus Characterization 
Several experiments were performed to characterize rescued influenza A reporter 
viruses encoding mPlum or NLuc. TCID50 and plaque assays were used to quantify the 
viral titers, and plaque morphology analysis was used to investigate the size and shape of 
plaques formed by the recombinant wild-type and reporter influenza viruses. Moreover, 
the replication kinetics of the generated viruses were investigated through low MOI 
growth curves on Madin-Darby canine kidney cells (MDCK cells), a standard cell line 
used to grow influenza A virus. Lastly, the previously described expression experiments 
including the Nano-Glo® Luciferase Assay and immunofluorescence for mPlum were 







3.2 – METHODS 
Sub-cloning of PA-reporter gene constructs into pHH21 
The PA-reporter constructs were sub-cloned out of pCAGGS and into the pHH21 
plasmid for use in a reverse genetics system to rescue the reporter virus. Bsa1 restriction 
enzyme sites were added to the 3’ and 5’ ends of the PA-reporter segments with PCR. 
PCR products were run on a 1% gel and purified using the QIAquick Gel Extraction Kit 
(Qiagen) (Figure 13). The purified reporter plasmids were digested with BsaI at 37°C for 
18 hours and heat inactivated for 20 minutes at 65°C. An empty pHH21 plasmid was also 
cut with BsmBI for 18 hours at 55°C and heat inactivated for 20 minutes at 80°C. 
Digested products were verified on a 1% agarose gel and purified as described above 
(Figure 14).  
The isolated PA-reporter segments were ligated into the linearized pHH21 
plasmid at a 3:1 molar ratio for 16°C overnight. Ligations were then transformed in dH5-
α cells (ThermoFisher Scientific). 1µl of ligation products were added to a 50µl aliquot of 
thawed cells on ice and incubated for 30 minutes. Cells were heat shocked for 20 seconds 
in a 42°C water bath and immediately returned to ice for 5 minutes. 950µl of pre-warmed 
SOC media was added and cells were transferred to a 37°C shaker at 225rpm for 1 hour. 
200µl of each transformation was spread on a pre-warmed LB-agar-carbenicillin plate 
and incubated at 37°C overnight. Bacterial colonies were grown in 3ml cultures 







Plasmid DNA from the bacterial cultures was purified with the QIAprep Spin 
Miniprep Kit (Qiagen) and the concentration was measured with the ND-1000 
spectrophotometer (Thermo Fisher Scientific). Samples were verified by sequencing at 
the Johns Hopkins University Institute of Genetic Medicine as previously described using 
pHH21 forward and reverse primers (Table 2). The ZymoPURE™ Plasmid Maxiprep Kit 
(Zymo Research) was used to maxiprep the pHH21-PA-NLuc and pHH21-PA-mPlum 
samples that were verified by sequencing. 
 
Reverse Genetics and Virus Rescue – Figure 15 
293T cells were plated at 3x105 cells/ml in a poly-lysine coated 6-well plate and 
transfected at 60% confluency. Cells were transfected using TransIT-LT1 transfection 
reagent with the pHH21-A/Victoria/361/11 segment containing plasmids as shown 
below. 



















































Pol I HA 
(WT) 
Pol I HA 
(WT) 
Pol I HA 
(WT) 
-HA and -NA Negative Controls 
Pol I NA 
(WT) 
Pol I NA 
(WT) 
Pol I NA 
(WT) 
 
Plates were incubated for 24 hours at 32°C, 5% CO2. After 24 hours, 4µl N-
acetylated trypsin (NAT, Sigma-Aldrich) was added per well for a final concentration of 
10µg/ml. Plates were moved to 37°C, 5% CO2 and incubated for 4 hours. Each well was 
then overlaid with 500,000 MDCK cells per well resuspended in 100µl OptiMEM and 
BSA and placed back at 37°C. 1ml of virus containing supernatant was collected from the 
wells every 24 hours and cytopathic effects were noted. Wells were replaced with 1ml 
infectious media (IM) containing DMEM with 100U penicillin/ml, 100µg 
streptomycin/ml (Quality Biological), and 2mM L-Glutamine (Gibco Life Technologies), 
30% Bovine Serum Albumin, and 2µl NAT per well. Collected supernatants were stored 
at -80°C. 
 
Virus Plaque Assay and Clone Isolation 
MDCK cells were seeded at 5x105 cells/ml, 2ml/well, in a 6-well plate and grown 
to confluency at 37°C. Cells were washed with 1ml/well of PBS+ twice and 1ml of 
DMEM containing 100U penicillin/ml, 100µg streptomycin/ml (Quality Biological), and 
2mM L-Glutamine (Gibco Life Technologies) was added. Plates were moved to 37°C 






Virus-containing supernatants from the reverse genetics transfections were 
removed from -80°C and allowed to thaw at 4°C. Serial dilutions of 10-1, 10-2, 10-3, 10-4, 
and 10-5 were made in a 24-well plate containing IM with 5µg/ml NAT. Cells were 
removed from the incubator and infected with 250µl of the appropriately diluted virus 
inoculum and placed at 37°C for 1 hour with gentle agitation every 15 minutes. 
Meanwhile, a 1% agarose medium was prepared from equal volumes of 2% agarose 
(UltraPure Agarose, Invitrogen) in ddH2O and MEM (Gibco Life Technologies) 
containing 2% Penicillin and streptomycin, GlutaMAX (Gibco), Bovine serum albumin, 
and 100mM HEPES (Gibco). N-acetylated trypsin (Sigma) at a concentration of 5µg/ml 
was added. After 1 hour, the inoculum was removed from the cells completely, and 2ml 
of the 1% agarose medium was added per well. Plates were incubated at 37°C for 3-4 
days until plaque formation was observed. 
Virus clones were isolated by picking plaques using a 2ml aspirating pipette tip 
and agarose plugs were transferred to tubes containing 1ml IM with 5µg/ml NAT. The 
tubes were placed at 4°C for 1 hour to allow the virus inoculum to seep out of the agarose 
and into the media. To generate seed stocks from the picked virus clones, MDCK cells 
were infected in a T25 flask at 100% confluency. 1ml of the purified virus inoculum was 
added to the flask and incubated at 37°C for 1 hour with gentle rocking every 15 minutes. 
After 1 hour, 5ml of fresh IM with 5µg/ml NAT was added to the T25 flask and placed at 
37°C for two to four days until cytopathic effect was observed. The virus-containing 







Viral RNA Isolation 
Viral RNA from the generated seed stocks was isolated using the QIAamp Viral 
RNA Mini Kit (Qiagen). One-step RT-PCR using PA segment-specific primers was 
performed in order to generate amplified cDNA from the purified RNA. The cDNA was 
sequenced as previously described, using primers listed in Table 2.  
 
TCID50 Assay 
MDCK cells were plated at 1x105 cells/ml, with 100µl/well in 96-well plates and 
grown to confluency at 37°C, 5% CO2. Virus seed stocks were removed from -80°C and 
thawed at 4°C. Meanwhile, the 96-well plates were washed twice with 100µl/well of 
PBS+. 180µl IM and 5µg/ml NAT were added per well and plates were moved to 37°C. 
Serial dilutions of the virus seed stocks were made and respective dilutions were added to 
the 96-well plates and replaced at 37°C, 5% CO2 for 5 days. On the fifth day, 75µl of 4% 
paraformaldehyde was added per well for 3 hours to fix the cells. The supernatant-
paraformaldehyde solution was removed from the wells and 100µl of Napthol Blue-Black 
stain was added per well and incubated at room temperature overnight. Plates were 




Seed stock plaque morphology was examined by infecting confluent MDCK cells 






4 days and then fixed with 1ml 4% paraformaldehyde/well overnight at room 
temperature. Following fixation, a micro-spatula was used to remove the agarose plug 
from each well, and 1ml of Napthol Black-Blue stain was added per well overnight at 
room temperature. Plates were washed with tap water, dried, and plaques were visualized. 
Plaque images were taken using an Olympus DP-70 color camera attached to a Nikon 
Dissection Stereoscope using a total magnification of 10x at the Institute for Basic 
Biomedical Sciences Microscope Facility within the Johns Hopkins University School of 
Medicine (Figure 20). Image J was used to quantify plaque area (Figure 21). 
 
Nano-Glo® Luciferase Assay 
Confluent MDCK cells in 96-well plates were infected with the rA/Victoria-WT 
and rA/Victoria-PA-NLuc viruses in triplicate with mock infected cells. The viruses were 
serially diluted in IM with 5µg/ml NAT five-fold across each row, with a 2x10-1 dilution 
of virus in the first column, ending with virus diluted 1.3x10-5 in the last column. Plates 
were incubated at 37°C, 5% CO2 for 12 or 24 hours before the Nano-Glo
® Luciferase 
Assay Reagent was added. Luminescence was measured with the Molecular Devices 
Microplate Reader and values were normalized to Mock infected wells (Figure 22).  
 
Immunofluorescence of rA/Vic-mPlum 
MDCK cells were grown to 100% confluence in a 6-well plate with two glass 
coverslips per well. The cells were infected with rA/Victoria-WT and rA/Victoria-PA-






suspension with pCAGGS-mPlum DNA (4µg/well) using Lipofectamine3000. Plates 
were incubated at 37°C, 5% CO2 with media replaced on the transfected wells every 24 
hours. No media replacement was done for the infected wells. At 12, 24, and 72 hours, 
the cells were washed three times with PBS+ and fixed with 1ml 4% paraformaldehyde 
per well for 15 minutes. The wells were washed again three times with PBS+ and then 
permeabilized with PBS+0.2% Triton X-100 for 15 minutes (1ml/well). A humified 
chamber was assembled by adding a damp paper towel to the top of a 1,000µl pipet tip 
box filled halfway with water. A sheet of parafilm was placed on top of the paper towel 
to seal in moisture. After a third round of washes with PBS+, the coverslips were 
transferred to the humidified chamber. A blocking solution of PBS with 2% normal 
donkey serum and 0.5% BSA was added to each coverslip at room temperature for 1 hour 
to limit non-specific antibody binding. Goat anti-H3-Aichi (HA for H3N2) was diluted in 
blocking buffer 1:200 and added to each coverslip. The coverslips were incubated in this 
primary antibody at 4°C overnight. After incubation with the primary antibody, the 
coverslips were washed seven times with 200µl PBS-Tween wash buffer. A FITC-
conjugated donkey anti-goat IgG secondary antibody was added. The coverslips were 
incubated with secondary antibody at 4°C for 1 hour. After secondary antibody 
incubation, the coverslips were washed another seven times with wash buffer and 
mounted onto microscope slides with 2µl mounting media containing DAPI to 
counterstain the nuclei. Coverslips were sealed with clear nail polish to prevent cells from 






Coverslips were imaged with the Zeiss AxioImager M2 microscope (Figure 23). 
Orientation and initial focusing was performed under the 10x objective before switching 
to the 40x objective. Fluorescence channel manipulation and image capture were 
conducted within the Velocity software program. The DAPI (Blue) channel was used to 
image cell nuclei and refine the focus. Keeping the same field and focus, the channel was 
switched to FITC (Green) to visualize HA antibody staining. The channel was then 
switched again to capture images with the Cy5 (Red) channel to detect fluorescence from 
mPlum protein expression. Images were contrast adjusted using ImageJ and channels 
were merged to create composite images. 
 
Low MOI Growth Curve  
MDCK cells were grown to confluence in 6-well plates and infected with the 
respective recombinant A/Vic virus at a low MOI = 0.001. Prior to infection, cells were 
washed twice with PBS+ and the viruses were diluted in IM and 5µg/ml NAT to an MOI 
of .001. The inoculum was added to the cells and incubated for 1 hour at 37°C, 5% CO2. 
After 1 hour, the inoculum was aspirated and cells were washed three times with PBS+. 
Fresh IM with 5µg/ml NAT was added to each well and incubated at 37°C. At each hour 
post infection (hpi) designated in Figure 24, the media was removed and stored at -80°C 
for subsequent tittering. Fresh IM with 5µg/ml NAT was added following collection. 








Graphing and Statistical Analysis 
Growth curves were analyzed with a two-way multiple-comparison ANOVA 
using GraphPad Prism 7 software. Nano-Glo® Luciferase Assay experiments were 






3.3 – RESULTS 
Virus Rescue 
Cytopathic effects (CPE) were observed in cultures transfected with rA/Vic-WT 
and rA/Vic-NLuc plasmids at 24 hours post MDCK overlay, but no CPE was observed in 
the rA/Vic-mPlum plasmid transfected cells until 48 hours. CPE included nuclei 
enlargement and cell rounding. After 72 hours of incubation, all of the cells transfected 
with either the rA/Vic-WT or rA/Vic-NLuc plasmids were dead. However, it took until 
the 96-hour time point to observe complete cell death in the rA/Vic-mPlum transfected 
cells.  
Following RT-PCR of purified viral RNA, Sanger Sequencing analysis 
demonstrated the seed and working stocks of the rA/Vic-PA-mPlum viruses had the exact 
sequence that was present in the plasmid used to rescue the viruses, which included the 
W422L mutation. The sequence of the PA segment of the rA/Vic-PA-NLuc virus was 
identical to that present in the plasmid used to rescue the recombinant virus. Working 
stock sequencing data are shown in Figures 16-18. This confirms that the recombinant 
viruses had the expected PA-reporter segment sequence with no additional mutations. 
 
Titers of Generated Recombinant Viruses  
The TCID50 value, or the Tissue Culture Infective Dose, is a measurement of the 
amount of virus needed to kill 50% of cells. The calculated TCID50 values for the 
working stocks are shown in Figure 19. The titer of the rescued rA/Vic-PA-NLuc virus 






that no virus attenuation occurred when the nanoluciferase gene was added to the specific 
internal region of the PA segment. However, there is a significantly lower titer of the 
rA/Vic-PA-mPlum virus as compared to either the wild-type or NLuc virus, indicating 
the virus is somewhat attenuated. 
The viral titers calculated via plaque assay were consistently approximately 1 log 
value lower than the TCID50 calculated value (Figure 19). Despite the lower titers of the 
mPlum rescued virus, there were no differences in the calculated plaque areas (Figure 
21), and both reporter viruses formed plaques with the same morphology as the wild-type 
virus (Figure 20). However, it took an additional two days for the rA/Vic-PA-mPlum 
virus to reach these sizes, indicating there was an attenuation in the ability of the virus to 
form plaques.  
 
Nano-Glo® Luciferase Assay 
Nanoluciferase activity was confirmed at both 12 and 24-hour post-infection 
using the Nano-Glo® Luciferase Assay (Figure 22). Both rA/Vic-WT and mock infected 
MDCK cells had very low, nearly undetectable levels of luminescence after all 
luminescence readings were normalized to mock infected wells. The higher relative light 
unit (RLU) value of the 12hpi timepoint in comparison to 24hpi with rA/Vic-PA-NLuc is 
likely due to cell death at 24hpi. These results verify activity of the nanoluciferase 








Immunofluorescence of rA/Vic-mPlum 
At 12hpi, HA antibody staining was observed in both rA/Vic-WT and rA/Vic-PA-
mPlum infected cells, with fewer infected cells detected in the rA/Vic-PA-mPlum 
infections. Infected cells expressing the H3 HA surface glycoprotein appear as green cells 
when imaged with the FITC channel. Figure 23 shows the DAPI, FITC, and Cy5 merged 
channels for the MDCK infections with mock, rA/Vic-WT and rA/Vic-PA-mPlum, 
respectively. At 12 and 24hpi, no mPlum protein was detected under the Cy5 channel. At 
72hpi, all of the cells infected with either the mPlum reporter or wild-type virus had died, 
and none were successfully counterstained with DAPI. Figure 23 also shows the 
successful positive control transfection of pCAGGS-mPlum at 24hpt, as well as the 
inability to detect mPlum expression in the 24hpi rA/Vic-PA-mPlum infected MDCK 
cells. This experiment will be repeated with additional time points at 36 and 48hpi in 
order to try and capture mPlum expression prior to cell death. The results at 12hpi 
however, confirm that the mPlum reporter virus rA/Vic-PA-mPlum is infectious and 
produces virus particles with HA surface glycoprotein, even though no mPlum 
fluorescence is detectable.  
 
Low MOI Growth Curve 
The rA/Vic-WT and rA/Vic-NLuc viruses reached peak viral titers of 5.4 and 4.3 
log TCID50/ml at 48 hpi, respectively (Figure 24). These two viruses grew with similar 
kinetics, and the greater titer of rA/Vic-NLuc was evident as soon as 24 hpi. In contrast, 






demonstrated a delayed ability to produce infectious virus. It also took longer to observe 
clearance of cells in the TCID50 plates infected with rA/Vic-mPlum, and these plates 















CHAPTER 4: DISCUSSION 
4.1 – OVERVIEW 
Reporter viruses are useful tools for visualizing replication dynamics, analyzing 
tissues involved in infection, and screening novel antiviral therapies. In this project, two 
influenza A reporter viruses were generated using the mPlum fluorescent protein and the 
luciferase nanoluciferase in the backbone of the A/Victoria/361/11 H3N2 strain. Based 
off previously published work by Andrew Mehle and colleagues, the reporter genes were 
inserted into the PA segment and packaging signals were moved to the end of the coding 
region to ensure full translation of the fluorescent protein.  
 
4.2 – rA/Vic-mPlum 
Despite rescue of both the recombinant mPlum and nanoluciferase encoding 
viruses, rA/Vic-mPlum exhibited significant attenuation in vitro, reaching significantly 
lower peak viral titers as compared to the wild-type A/Vic rescued virus. In addition to 
reaching lower peak viral titers, rA/Vic-mPlum took longer to demonstrate cytopathic 
effects in infected MDCK cells. Plaques also took longer to form, though they eventually 
grew to the same size as those of rA/Vic-WT. Furthermore, at 12 and 24-hours post-
infection, no mPlum protein was detectable with immunofluorescence microscopy, 
despite signs of infection. This is in contrast to the fact that mPlum was detected after 
transfecting cells with plasmids encoding the PA-NLuc protein. This may be due to 
decreased transcription and/or translation of the mPlum coding region in virus infected 






segment in the context of virus infection. However, the production of a replication-
competent virus indicates that there is successful incorporation of the PA segment into 
the influenza viral particles, since it is required as part of the polymerase machinery. The 
packaging signals for the PA segment were moved to the end of the mPlum gene, so it is 
possible that there was full transcription and translation of the mPlum protein, but levels 
are too low to detect with immunofluorescence. Sequence analysis of the working stocks 
used for MDCK cell infections verified the continued expression of the reporter gene 
despite the few rounds of passaging between plaque purification, seed stock, and working 
stock generation. Despite correct sequencing, it is possible that replicating viruses during 
the MDCK cell infections used in immunofluorescent imaging were lost, and more fit 
wild-type-like viruses emerged as the dominant virus.   
The attenuation of the rA/Vic-mPlum virus may point to the importance of 
reporter gene size when constructing influenza A reporter viruses. The mPlum 
fluorescent protein is 681bp, while nanoluciferase is 513bp. According to the 
experiments performed in this thesis, even this 168bp difference may be enough to 
disturb viral replication kinetics. Despite the size differences between mPlum and 
nanoluciferase, it is possible that the mPlum protein interferes with the formation of the 
polymerase resulting from interactions between PA, PB1, and PB2. No analysis of charge 
differences or spatial analyses was performed, but may be useful in elucidating the 
challenge with using mPlum as a reporter gene in this context.  
Another challenge faced with the rA/Vic-mPlum reporter virus is use of mPlum as 






proteins with shorter wavelengths, the mPlum protein has a brightness of 4,100 compared 
to other frequently used proteins in this spectrum such as mRaspberry (12,900) and E2-
Crimson (28,900).63 Moreover, PA expression for the pCAGGS-PA-mPlum construct 
was not performed, and attempts to stain for PA during transfection-based 
immunofluorescence experiments in Vero cells were obscured by high levels of non-
specific antibody binding. The W422L mutation in the PA region of pCAGGS-PA-
mPlum is also an additional concern and may have a deleterious effect on expression of 
PA or mPlum. 
Despite the inability to detect mPlum expression in infected MDCK cells and the 
lower replication kinetics of the rA/Vic-mPlum virus, the rescue of this reporter virus 
suggests that smaller and brighter fluorescent proteins should be considered for more 
useful applications of influenza A reporter viruses.64  
 
4.3 – rA/Vic-Nluc 
When compared to rA/Vic-WT, the rA/Vic-NLuc virus grew to higher titers in 
MDCK cells but formed plaques of equivalent size in the same time period. This suggests 
that the rA/Vic-NLuc virus replicates at least as well, and perhaps better, than its parental 
virus. The reason for this increased infectious virus production is not clear and should be 
investigated more carefully. The other viral RNA segments should be sequenced to 
ensure that no mutations were acquired that might be leading to increased virus 






rA/Vic-WT viruses used in alternate virus rescue experiments to see if the lower titer of 
rA/Vic-WT was specific to this project.  
The rescue of the rA/Vic-NLuc virus was successful and suggests a range of 
future imaging applications. First, it is possible to use the generated pHH21-PA-NLuc 
plasmid in additional 12-plasmid based reverse genetics approach. As such, segments 
from circulating influenza strains can be isolated and sub-cloned into pHH21, where the 
pHH21-PA-NLuc plasmid can be used in place of the circulating strain’s PA segment. 
Products from the reverse genetics approach would yield nanoluciferase-expressing 
viruses where seven of eight segments match circulating strains, with limited differences 
in the PA sequence. By constructing the rA/Vic-NLuc virus in an H3N2 background from 
2011, this reporter virus is more useful for investigating currently circulating H3N2 
strains than the previously generated nanoluciferase reporter virus by Tran et. al., which 
used a 1933 strain of H1N1. 
 
4.4 – FUTURE DIRECTIONS 
Overview 
Nanoluciferase-based reporter viruses could be used to analyze circulating 
influenza viruses in novel ways. For example, the reporter virus may serve as an alternate 
method for screening antibody neutralization capabilities. Luminescent output is also a 
more easily quantifiable method than CPE scoring that is typically done with antibody 
neutralization assays. Similarly, the efficacy of new antiviral drugs can be quickly tested 






like nanoluciferase in construction of a reporter virus does have its limitations. Primarily, 
the substrate for the enzyme cannot always be administered systemically, so animal 
model-based imaging experiments are limited. In these cases, fluorescent proteins such as 
mPlum would lend more extensive options and should continue to be explored. 
 
Live-Cell Imaging 
While static imaging of cells infected with the rA/Vic-reporter viruses revealed 
successful infection (rA/Vic-mPlum) and production of nanoluciferase (rA/Vic-NLuc), 
these viruses can be used in further live imaging experiments. For example, once 
expression of mPlum protein is validated in rA/Vic-mPlum, infection of primary human 
nasal epithelial cells (hNEC) with rA/Vic-mPlum may inform the mechanism behind 
viral spread. The use of hNEC cultures, rather than traditional cell lines, preserves the 
mucus production and ciliary motion present in the human respiratory tract. Live imaging 
the infection of these primary hNECs with the rA/Vic-mPlum reporter virus can help 
deduce the importance of mucociliary spread of IAV in comparison to cell-to-cell spread 
through various cellular networks.65  
 
Seasonal Influenza Transmission Dynamics 
The generated rA/Vic-NLuc reporter virus can also be used for tracking virus 
infection in vivo through bioluminescent microscopy and provides a unique approach to 
investigating infection and transmission dynamics of seasonal influenza viruses. 






background was recently used to infect ferrets and evaluate viral dynamics in real-time.66 
Results demonstrated that bioluminescent imaging in the ferret model was highly 
sensitive and significantly correlated to viral titers of collected nasal washes. The rA/Vic-
NLuc produced in this project can be used in a similar fashion to further investigate the 
viral transmission and replication dynamics of modern H3N2 viruses.  
  
Serum Antibody Neutralization Alternative 
These generated IAV reporter viruses also offer an alternative approach to 
standard serum antibody neutralization assays (NT). NT assays measure the titer of 
antibodies necessary to block cytopathic effects caused by the virus, through inhibiting 
viral fusion and entry into the cell.67 While these assays provide a reliable method for 
determining antibody concentrations, NT assays are more time-consuming, expensive, 
challenging to standardize between laboratories, and require the use of live virus that 
induces cytopathic effects.68 The only widely accepted alternative to NT assays are 
hemagglutinin inhibition (HI) tests, which are more affordable and easier to 
standardize,69 but less sensitive and subject to misinterpretation by the investigator. Use 
of an IAV reporter virus offers a unique alternative to standard NT and HI assays, and 
may provide a more rapid and affordable method for determining antibody neutralization 
titers. For example, the PA-NLuc segment based of the A/Victoria H3N2 virus that was 
generated in this project can be used in a reverse genetics approach with segments 
isolated from currently circulating or historical strains of influenza, to make additional 






of isolated serum. Following incubation, addition of the NLuc substrate will allow the 
luminescent output to be used as a rapid quantitative measurement of virus neutralization. 
This is less time-consuming than standard downstream ELISA used in NT assays, and 
will help detect a broader range of neutralizing antibodies than those only against HA 







Figure 1: Influenza virus 
structure. Adapted from 
Horimoto, Nature Reviews 
Microbiology, 2005. 71 
IAV has eight internal 
gene segment that replicate 
independently of one 
another in an infected cell. 
The surface of the virus 
particle is decorated with 
glycoproteins 









Figure 2: The structure of the influenza A 
polymerase complex. Adapted from 
Lukarska, Nature 2017. 72 The complex is 
created with interactions between the 









Figure 3: PA-SWAP-2A-Nluc50 (PASTN) construct by Tran et al.52 This 
construct served as the basis for the recombinant A/Victoria H3N2 reporter 





Figure 4: Project outline. PA-reporter constructs were first generated and 
moved into the pCAGGS mammalian expression plasmid. Following 
confirmation of expression, the PA-reporter constructs were subcloned into the 
pHH21 plasmid and used in a reverse genetics approach to generate complete 







Figure 5: Restriction enzyme 
digestion of pCAGGS-
mPlum. pCAGGS-mPlum 
plasmid DNA was digested 
overnight with restriction 
enzymes Nhe1 and Sac1 and 
products were run on a 1% 
agarose gel. The mPlum 
fragment at 681bp (arrow) was 








Figure 6: Overlap extension PCR for the addition of PA terminal 50 nucleotides to 
mPlum. The mPlum-OH and OH-PAt50 sequences were stitched together using a 
Phusion®-based overlap extension PCR. A gradient from 50-60°C was used to determine 
the optimum annealing temperature of 58°C. The negative control lane “mPlum with 
overhang only” indicates sample without the additional terminal 50 nucleotides of PA 
added. The molecular weight differences between this band and all other samples indicate 







Figure 7: Restriction enzyme digestion of 
pCAGGS-mPlum for the generation of 
linearized pCAGGS. The pCAGGS-mPlum 
plasmid was digested overnight with Nhe1 and Sac1 
an additional time, and the top band containing 
linearized pCAGGS alone (arrow) was extracted 
and purified. The mPlum band at 681bp was 
discarded. The purified pCAGGS DNA was then 







Table 1: Primer Sequences 
mPlum_Forward CATGGTGAGCAAGGGCGAG
GAGGTCA 
Add overhanging segments 
and stitch together the 
mPlum and terminal 50 

















Prepare gBlock of 
PA_GSG_2A for 
pCAGGS Gibson 



















Used with mPlum_PA_For 




Used to stitch together the 
mPlum-PAt50 and rest of 












Delete the additional T 
nucleotide at position 3019 






Prepare gBlock of 
PA_GSG_2A for 
pCAGGS Gibson 






Prepare gBlock of 
NLucPAt50 for pCAGGS 







Table 2: Sequencing Only Primers 
PA FluA9 R ATACGTCTCGTATTAGTAGAAACAAGGTACT 









pHH21-1 F GGTATATCTTTCGCTCCGAG 
























Figure 8: Sequence alignments showing frameshift mutation in pCAGGS-PA-
mPlum. A mutation from a G to a T within the PA region of the pCAGGS-PA-mPlum 
construct results in a frameshift. After site-directed mutagenesis, the G nucleotide 
preceding the GT mutation was deleted, effectively fixing the frameshift mutation, but 





Figure 9: Sequence alignments of PA segments of multiple H3N2 strains show 
conserved tryptophan at position 422. Fifteen PA sequences from H3N2 viruses 
since 1971 were obtained through GenBank. Alignment of these sequences indicates 
conservation of the tryptophan at position 422 as compared to the W422T mutation 









Figure 10: Validation of nanoluciferase expression 
of pCAGGS-PA-NLuc. Nano-Glo® Luciferase assay 
was used to detect luminescence in Vero cells 
transfected with the pCAGGS-PA-NLuc plasmid at 12, 
24, and 48 hours post transfection. Experiments were 
conducted twice with nine replicate wells per sample 
and representative data are shown. Error bars indicate 
standard deviation. * denotes statistically significant 
differences (p<0.05) in the luminescence output (RLU) 
as compared to the positive control pNL1.1-NLuc 









Figure 11: Validation of PA protein expression in pCAGGS-PA-NLuc. Western 
blotting of Vero cells transfected for 48 hours with pCAGGS-PA-NLuc revealed 
successful detection of PA (~75kDa). Vero cells were also infected with a laboratory 
stock of A/Victoria/361/2011. Protein levels were normalized with beta-actin (40 kDa). 
The image shown includes two replicates per sample with the exception of the well with 
heat-killed A/Vic virus only. Previous attempts to detect PA with alternate antibodies in 












Figure 12: Fluorescence microscopy of mPlum expression in pCAGGS-PA-
mPlum. Vero cells transfected with pCAGGS-mPlum (A-C), the generated pCAGGS-
PA-mPlum plasmid (D-F), and mock (G-I). Imaged at 48hpt, 40x magnification, and 
counter stained with DAPI. mPlum protein production is observed in both the positive 







Figure 13: Addition of BsaI restriction 
sites to PA-mPlum and PA-NLuc 
constructs by PCR. Bsa1 restriction 
enzyme sites were added to the 3’ and 5’ 
ends of the PA-mPlum and PA-NLuc 
segments using PCR. PCR products of the 
new BsaI-PA-mPlum (1) and BsaI-PA-
NLuc (2) were run on a 1% gel and bands 
indicated close to 3kb were extracted 
purified using the QIAquick Gel 






Figure 14: Restriction enzyme digestion of PA-mPlum and PA-Nluc constructs and 
the pHH21 plasmid. The PCR generated BsaI-PA-mPlum and BsaI-PA-NLuc plasmids 
were digested with BsaI at 37°C for 18 hours and heat inactivated for 20 minutes at 65°C. 
An empty pHH21 plasmid was also cut with BsmBI for 18 hours at 55°C and heat 









Figure 15: Schematic of the reverse genetics process for creating influenza A 
viruses. In this process, cells are transfected with plasmids expressing influenza viral 
RNAs in the presence of helper plasmids. MDCK cells are overlaid and virus-
containing supernatant is collected at 24, 48, 72, and 96 hours later. cDNAs encoding 
the PA, PB1, PB2, and NP helper plasmids are contained in the pCAGGS eukaryotic 
expression vector with a very active promoter for the purpose of generating large 
quantities of the influenza RdRp necessary for the replication of viral genomic RNA 
and the transcription of viral mRNAs. The other influenza segments are cloned into 
individual pHH21 plasmids that contain a human RNA polymerase I promoter and a 


















Figure 16: Sequence analysis of the working stock of rA/Vic-WT. No mutations 




Figure 17: Sequence analysis of the working stock of rA/Vic-NLuc. No mutations 







Figure 18: Sequence analysis of the working stock of rA/Vic-mPlum. Sequencing 
results shows persistence of G3021T mutation within the PA segment. No other 










Figure 19: Working stock titers of recombinant A/Vic viruses 
by TCID50 and plaque assays. TCID50 and plaque assays for the 
generated viruses were performed on MDCK cells. Log 
TCID50/ml values represent mean titers across triplicates. Log 
PFU/ml values represent mean values of two replicate 
experiments. * denotes statistically significant differences 








Figure 20: Plaque assay of MDCK cells infected with WT and 
reporter viruses. Representative images from plaque assays conducted 
on MDCK cells infected with the rA/Vic generated working stocks. 
Mock, rA/Vic-WT, and rA/Vic-NLuc images were captured after 5 
days of incubation at 37°C and represent plaques formed by virus 
diluted at 10-4. The mPlum plates were incubated for 8 days and the 10-
2 dilution wells were imaged. These are representative images and the 









Figure 21: Comparison of plaque areas formed by reporter and 
WT viruses. No significant differences between plaque areas (mm2) 
were observed between MDCK cells infected with either reporter 
virus compared to rA/Vic-WT. However, rA/Vic-mPlum plaque 
assay plates were incubated at 37°C for an additional three days than 
the rA/Vic-WT and rA/Vic-NLuc plates. Plaque assays with working 
stocks were repeated twice and plaques from representative wells 
















Figure 22: Luciferase activity of the rA/Vic-NLuc reporter virus. 
Luciferase activity of MDCK cells infected with rA/Vic-WT and 
rA/Vic-NLuc viruses as determined by Nano-Glo® Luciferase Assay. 
The assay was performed with five-fold dilutions of virus at 12 and 
24 hpi and luminescence values were normalized to mock infected 
cells. The experiment was conducted twice with three replicate wells 
per sample. * denotes statistically significant differences between 









Figure 23: Fluorescence microscopy for evaluation of the rA/Vic-mPlum reporter 
virus. MDCK cells imaged (40x) at 12, 24, and 36 hours post transfection with 
pCAGGS-mPlum (A-C), and infection with rA/Vic-WT (D-F), rA/Vic-mPlum (G-I), 
and mock (J-L). Coverslips were stained for HA (green) and counterstained with DAPI 
for mounting. Cells are visibly infected with rA/Vic-mPlum (G-I), however no mPlum 
protein is detected (red). Images are representative of two replicates from a single 








Figure 24: Replication kinetics of WT and reporter viruses. A low-
multiplicity growth curve was performed in triplicate by infecting MDCK 
cells with an MOI of 0.001 of the generated recombinant rA/Vic viruses. 
TCID50 plates for rA/Vic-WT and rA/Vic-NLuc were incubated for five 
days at 37°C, while the rA/Vic-mPlum plates were kept for an additional 
three days at 37°C before fixation and staining. Asterisks indicate a 
statistically significant difference of the overall growth curve compared to 
rA/Vic-WT using a two-way multiple-comparison ANOVA, p<0.01. 
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